ALX Oncology Holdings Inc.
ALXOHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. With a market capitalization of $161.8M, it sits in micro-cap territory. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic development as a combination therapy with other anti-cancer agents, including ASPEN-06, under phase 2 clinical study for treating Gastric/GEJ cancer.
Market Cap
$161.8M
Beta
0.48
P/E (TTM)
—
P/E (Fwd)
-2.17
EPS (TTM)
$-1.11
EPS (Fwd)
$-0.54
ROE
-80.7%
ROA
-40.4%
Cash
$138.2M
Total Debt
$11.0M
Free CF
-$41.2M
52W Change
-33.1%
Annual Financials
Cash vs Debt
Where ALXO stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, ALXO finished 37.02% below its 150-day moving average ($1.81) and 37.70% below its 200-day moving average ($1.83). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is ALXO overbought or oversold?
At the October 20, 2026 close, ALXO's RSI(14) was 40.3, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $138.2M in cash and $11.0M in debt, ALXO maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. The company is burning cash, with free cash flow at -$41.2M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -80.7% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
The relatively low beta of 0.48 suggests ALXO is a less volatile holding compared to the broader index. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for ALX Oncology Holdings Inc. and its sector.